PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

Every breast cancer is unique. Watch this video to learn how a genomic test, the Oncotype DX test, can help personalize treatment options or visit http://www.mybreastcancertreatment.org/ for more information. | Until Everyone Knows

▶️ The Oncotype DX test analyzes the genes of your breast cancer to predict how aggressive it is and whether chemotherapy would help. It helps your doctor personalize your treatment so you can avoid unnecessary chemo if your cancer is less likely to return. Learn more: https://www.primrmed.com/cancer-education/oncotype-dx-for-breast-cancer #breastcancer #oncotypedx #chemotherapy #personalizedtreatment #breastcancerawareness #bcam #patienteducation #simplecancerexplanations #health #cancer #oncol